课题基金 / 基金详情

Development of novel molecular targeted therapies for the treatment of KRas mutated non small lung cancer using a HSP90 inhibitor

Development of novel molecular targeted therapies for the treatment of KRas mutated non small lung cancer using a HSP90 inhibitor
使用 HSP90 抑制剂开发治疗 KRas 突变非小细胞肺癌的新型分子靶向疗法
批准号:
23592078
负责人:
MORITA ICHIRO
金额:
$3.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2013

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hsp90 inhibitors are substances that inhibit the activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of various types of malignancies. In the present study, we have evaluated the antitumor effects of a novel HSP90 inhibitor, AUY922 for the treatment of lung cancer. AUY922 suppressed cell viability and induced apoptosis in KRas addicted pulmonary adenocarcinoma cells. More, the inhibitor showed antitumor effect in EGFR-TK mutation or EML4-ALK positive lung cancer cells. These results indicate that AUY922 looks to be a promising treatment for non small cell lung cancer including pulmonary adenocarcinoma harboring KRas mutation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
EB病毒类朊蛋白EBNA1通过分子伴侣HSP90调控相分离促进鼻咽癌恶性进展的机制研究
  • 批准号:
    2026JJ60271
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    张宵月
  • 依托单位:
富血小板血浆外泌体通过靶向雪旺细胞sFRP1-巨噬细胞HSP90轴减轻神经病理性疼痛的机制研究
  • 批准号:
    2026JJ81668
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    左玲玲
  • 依托单位:
分子伴侣Hsp90/FKBP51复合物通过稳定PPARγ减轻糖尿病心缺血再灌注损伤的机制研究
  • 批准号:
    JCZRYB202500986
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
西花蓟马热休克蛋白Hsp90与番茄斑萎病毒NSs蛋白互作调控介体传毒机制研究
  • 批准号:
    2025JJ60138
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    陈建斌
  • 依托单位: